Therefore, the treatment should cause the release of cGAMP and CDNs from tumor cells into the tumor’s microenvironment to activate STING in the cDC1 TIDCs that have infiltrated the cancerous growth, thereby enhancing the anti-tumor immune response. Here, STING1 is linked to neoplasm.